Key facts
- It has raised $14.1M; the latest was Later Stage VC ($14.1M) in Dec 2025.
- Notable investors include Hangzhou Dongfang Jiafu Asset Management, Optics Valley Industry Investment, Lianyungang Jinhai Venture Capital, Jiangsu Jinqiao Private Equity Fund Management, Tenyall Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Junji Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Junji Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Junji Bio
Developer of biosynthesis designed to provide overall solutions for molecular diagnosis, nucleic acid chemistry, synthetic biology and antibody drug development. The company focuses on the research and development of life science robot technology and the application of artificial intelligence in life science, thereby providing customers with high-quality customized chemical synthesis, biosynthesis and molecular biology-related services.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- gentlegen.com/
- Ownership
- Privately Held (backing)
Junji Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Junji Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Junji Bio in its N-PORT filings yet. We sweep new filings monthly.